A Study of Obinutuzumab in Chinese Participants With CD20+ Malignant Disease
Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
This multi-center, open-label, single-arm study will evaluate the pharmacokinetics and safety
of obinutuzumab in participants with cluster of differentiation (CD) 20 positive (+)
malignant disease. Participants will receive multiple doses of obinutuzumab. The anticipated
time on study treatment is 24 weeks.